Intangible-Asset and IP Collateral Insurance in India 2026: Insuring Brand and Patent Value to Unlock Lending

The balance sheet of a modern Indian company looks very different from the one that bank lending was built for. For a software firm, a consumer-brand business, a pharmaceutical innovator or a deep-tech startup, the bulk of enterprise value sits in intangibles: patents, registered trademarks and the brand they protect, copyrighted code and content, registered designs, and the trade secrets and know-how that the company runs on. The factory, the land and the machinery that a traditional lender takes as security are a small part, or none, of what makes the company worth what it is worth.

This creates a financing gap. A lender advances against tangible collateral it can value, seize and sell, but has historically been wary of intangibles, because an intangible asset is hard to value, hard to take a security interest over, and hard to realise on default. So companies whose value is overwhelmingly intangible struggle to borrow against the very assets that make them valuable, and instead raise equity (diluting founders) or borrow at high rates against thin tangible security. The asset is real and often large; the financing system cannot see it as collateral.

Intangible-asset and IP-value insurance has emerged to bridge this gap. The idea is straightforward: if an insurer stands behind the value of an intangible asset, that asset becomes something a lender can lend against, because the lender's downside is protected by the insurance rather than by an uncertain ability to seize and sell a patent or a brand. The insurance converts an unbankable asset into bankable collateral. This is a genuinely new product area for the Indian market, still early, but it addresses a real and growing problem as the economy shifts toward intangible-heavy businesses.

Intangible-asset insurance is not a single product but a family of structures, and the right one depends on whether the buyer is the company protecting its own asset value or a lender protecting its loan. Two structures anchor the family.

Value-impairment cover

A value-impairment structure protects against a fall in the insured value of a specified intangible asset below an agreed level, triggered by defined events. The policy fixes an insured value for the asset (the sum insured for the intangible) and responds if a covered event impairs it, for example a third-party challenge that invalidates a patent, a loss of trademark rights, or a defined event that destroys the asset's value. Built around the value of the asset itself, it is what allows the asset to function as collateral, because the lender knows the insurance responds if a covered event wipes out the value.

Residual-value cover

A residual-value structure is built around the lender's position rather than the asset in the abstract. It guarantees, in effect, a defined residual or realisable value of the IP collateral at a point in time or on a default, so that if the borrower defaults and the lender has to realise the IP, the lender recovers at least the insured residual value. This is the structure most directly designed to enable IP-backed lending: it gives the lender a floor on what the collateral is worth in a default scenario, which is precisely the uncertainty that kept lenders away from intangibles. The premium and terms reflect the gap between the loan amount, the assessed asset value, and the insured residual floor.

What is being insured: patents, brands, trade secrets. The asset classes that these structures are written over are mainly registered IP and brand: patents (where validity and remaining life are central), registered trademarks and the brand value they carry, registered designs, and copyrighted works. Trade secrets and know-how are harder, because they are not registered and their value depends on continued secrecy, but they form part of the intangible base that some structures attempt to address. The clearer the legal title and the registration, the more readily the asset can be insured and pledged, which is why registered, well-documented IP is the easiest starting point and unregistered know-how the hardest.

Across both structures the insurable interest sits with whoever stands to lose financially if the asset's value falls: the company that owns and has financed against the asset, and the lender whose loan is secured on it. The policy is frequently arranged so the lender is the beneficiary or is assigned the benefit, because the lender is the party whose risk the cover is designed to retire.

Intangible-asset insurance has three natural buyers, and each comes to it for a different reason. Understanding which one is driving a given placement shapes how the cover is structured.

Startups and IP-rich growth companies

For an early or growth-stage company whose value is its IP, the appeal is debt without dilution. A startup with strong patents or a valuable brand but few tangible assets cannot easily borrow against its real value, and so funds growth by selling equity. If its IP can be insured and thereby pledged, it can raise debt against the asset, preserving founder and investor equity. The insurance opens a financing route that was otherwise closed, usually around the core patents or brand that underpin the business.

Lenders

Lenders are the pivotal buyer, because the product exists to retire their risk. A bank, a non-banking financial company or a specialist venture-debt lender that wants to lend against IP needs a way to bound its downside if the borrower defaults and the collateral has to be realised. Residual-value cover gives the lender a floor on the collateral's realisable value, which can be the difference between a credit committee approving an IP-backed loan and rejecting it. For lenders the insurance is a credit-enhancement and risk-transfer tool that expands the universe of borrowers they can serve, and the lender is frequently the policy beneficiary even where the company pays the premium.

CFOs of established intangible-heavy businesses. For the chief financial officer of an established company with significant intangible value (a consumer-brand house, a pharmaceutical innovator, a technology firm), intangible-asset insurance is a balance-sheet and financing tool. It can support borrowing against brand or patent value on better terms, protect the carrying value of capitalised intangibles against impairment events, and form part of how the CFO finances the business against its real asset base rather than only its tangible one. For this buyer the decision sits alongside the company's wider capital structure and its treatment of intangibles in its accounts.

The common thread is that the product is bought to make an intangible asset do financial work, whether that is unlocking debt, enabling a lender to extend it, or supporting a balance sheet. It is not bought, in this form, to fund a lawsuit, which is the domain of IP-litigation cover.

Everything about intangible-asset insurance turns on valuation, and valuation is the central difficulty that makes this product harder to write than conventional property or liability cover. A factory has a replacement cost and a market; a patent or a brand has neither in any clean sense, and the insured value the policy is built on has to be established by methods that are inherently more contested.

The valuation methods and their limits

Intangible valuation draws on three families of method. An income approach values the asset by the future cash flows attributable to it (the royalties a patent could earn, the price premium a brand commands, the margin a trade secret protects), discounted to present value. A market approach looks to comparable transactions, though genuinely comparable IP deals are scarce and often confidential. A cost approach looks to recreation cost, usually a weak proxy because the cost of creating IP bears little relation to its worth. Each has real limits: income projections can be optimistic, comparables are thin, and cost understates value. The insured value is therefore a judgement built from imperfect methods, not a hard number, which is what makes the underwriting demanding.

Why valuation drives the whole policy

The insured value sets the sum insured, the premium, and the lender's borrowing base all at once, so an aggressive valuation inflates the cover, the loan and the insurer's exposure together, while a conservative one limits all three. The insurer's interest is in a defensible, conservative valuation that it can stand behind through a covered event; the borrower's interest may pull toward a higher value to support a larger loan; the lender's interest is in a value that will actually be realisable on default. Reconciling these is the heart of structuring the cover, and it is why these placements involve specialist IP valuers, careful documentation of the asset and its legal title, and conservative haircuts between the assessed value, the insured value and the amount lent.

Title, registration and continuing conditions. Valuation sits on top of legal certainty about the asset. The clarity of title, the validity and remaining life of a patent, the registration and renewal status of a trademark, the absence of competing claims, and the maintenance of secrecy for a trade secret all feed both the value and the insurability. A policy typically carries conditions requiring the insured to maintain registrations, defend the rights, preserve secrecy and notify value-affecting events, because an intangible asset, unlike a building, can lose its value through neglect of the legal steps that sustain it. An asset whose registrations lapse or whose secrecy is blown can become worthless without any external attack, and the conditions exist to manage exactly that.

Intangible-asset value insurance is one piece of a wider set of IP-related covers, and buyers should be clear about what each does so they do not assume one product is carrying a risk that actually sits with another.

IP-litigation and infringement cover is the most important neighbour and the one most often confused with value cover. IP-litigation cover (in its enforcement and defence forms) funds the legal costs of pursuing an infringer or defending an infringement claim, and can cover damages awards. It addresses the risk of disputes, not the risk that the asset's value falls; a company can win every lawsuit and still see its patent invalidated or its brand devalued, and litigation cover does not respond to that value loss. Conversely, value-impairment cover responds to a value-destroying event such as an invalidation but is not a litigation war-chest. An IP-rich company often wants both: litigation cover to fund the disputes that protect the asset, and value or residual cover to make the asset bankable. The two are complements, and a buyer relying on litigation cover to protect collateral value, or on value cover to fund a lawsuit, has misread the product.

Intangible-asset cover also sits near a company's wider liability programme. Professional indemnity responds to claims arising from professional services, not to the value of an owned intangible. Directors-and-officers cover responds to claims against the company's leadership, which can include claims about how IP value was represented to investors or lenders, but again does not insure the asset's value. An IP-heavy company's risk register touches several products, and the value of the intangible is only one of the exposures.

For the lender and the CFO, an IP-backed financing usually needs a small stack: the value or residual cover that makes the asset bankable, possibly litigation cover to protect it against challenge, and clear documentation of how the covers interact with the security and the loan. The structuring question is which product carries which risk, and ensuring no risk falls between them. Getting that structuring right is where the detail lives: which structure, how the insured value is set and haircut against the loan, who holds the benefit, what continuing conditions apply, and how the cover meshes with any IP-litigation policy and the security documents.

Because intangible-asset insurance is new and bespoke, a buyer or lender should settle a defined set of questions before treating the cover as the thing that makes a loan safe. The points below are the ones that decide whether the policy does the job the financing assumes.

1. Which structure and whose risk it protects: is this value-impairment cover protecting the company's asset value, or residual-value cover giving the lender a floor on realisable collateral, and is the policy benefit held by the right party.
2. How the insured value was established and haircut: which valuation methods were used, how conservative the assessed value is, and how large the gap is between assessed value, insured value and the amount lent, because that gap is the real margin of safety.
3. Exactly what triggers a payment: which events impair value or crystallise the residual claim (invalidation, loss of rights, defined destruction of value), and what is excluded, so the lender knows the cover responds to the default scenarios it actually fears.
4. The continuing conditions on the asset: the obligations to maintain registrations and renewals, defend the rights, preserve trade-secret secrecy and notify value-affecting events, because an intangible can lose value through neglect of these steps and a breach can prejudice the claim.
5. How it meshes with the rest of the stack: whether IP-litigation cover is also needed, how the value cover interacts with the security documents and the loan, and which risks each product carries so none falls between them.

The discipline is the same one that applies to any cover relied on for financing: the lender's credit decision should rest on the actual wording, the actual insured value and the actual triggers, not on the comfort of the word insurance. An IP-backed loan supported by a value cover whose triggers do not match the lender's default scenario, or whose insured value rests on an optimistic valuation, gives less protection than the parties assume. Settling these questions before drawdown is what turns the cover from a label into genuine collateral protection.

The product is early, and the market for it in India is still forming, but the structural need is real and growing as more of the economy's value moves into intangibles. Buyers, lenders and advisers who understand the structures, the valuation problem and the boundary with litigation cover are positioned to use it as it matures.

Sarvada gives commercial-insurance brokers and corporate finance teams structured, searchable access to insurer wordings and the intelligence around emerging products, so they can compare intangible-asset and IP-value structures, their triggers, valuation bases, conditions and exclusions side by side, and match a financing to the cover that actually makes the asset bankable. Brokers, lenders and CFOs structuring IP-backed financing can Request Access to evaluate the platform for these placements.